Idexx Laboratories vs ResMed|
ResMed| is the larger business, with $5.65bn of revenue in fiscal 2026 against $4.30bn for Idexx Laboratories (1.3 times as much). Idexx Laboratories grew faster (10.4% against 9.9%). ResMed| kept more of each dollar of sales as profit: a net margin of 26.9% against 24.6%.
| Latest fiscal year | Idexx LaboratoriesIDXX, 2025 | ResMed|RMD, 2026 |
|---|---|---|
| Revenue | $4.30bn | $5.65bn |
| Revenue growth | 10.4% | 9.9% |
| Net income | $1.06bn | $1.52bn |
| Operating margin | 31.6% | — |
| Net margin | 24.6% | 26.9% |
| Return on equity | 66.2% | 24.3% |
| Free cash flow | $1.06bn | $1.65bn |
| Cash | $180m | $1.47bn |
| Total debt | $848m | $659m |
| Debt to equity | 52.8% | — |
| Dividend per share | — | $2.40 |
| Dividend yield | — | 1.1% |
| Share buybacks | $1.22bn | $700m |
| Employees | 11,000 | 11,370 |
| Market value | $53.19bn | $31.58bn |
| Price vs our value range | Above our value range | Within our value range |
| Moat score | 97 (Strong) | 88 (Strong) |
| Insider trades, 12 months | 0 buys, 36 sales | 0 buys, 32 sales |